{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T23:25:35Z","timestamp":1789860335486,"version":"4.0.1"},"reference-count":44,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2012,7,27]],"date-time":"2012-07-27T00:00:00Z","timestamp":1343347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of allogeneic stem cell transplantation (SCT) for chronic myeloid leukemia (CML) was almost abandoned in recent years for very effective targeted therapy with tyrosine kinase inhibitors (TKIs). However, approximately one third of patients still need another treatment including SCT. 38 consecutive CML patients were treated (most in preimatinib era) with allogeneic SCT, using partial T cell depletion (TCD) and preemptive donor lymphocyte infusion (DLI), without post\u2010transplant graft\u2010versus\u2010host disease (GvHD) prophylaxis. Conditioning included busulfan, cyclophosphamide, antithymocytic globulin, and fludarabine followed by donor stem cell transfusion. With a median follow up of 90.5 months (1\u2013134), 32 patients are alive. 97% engrafted. 5\u2010year leukemia free survival (LFS) and overall survival (OS) were 78.95% and 84.2%, respectively. All patients are in major molecular remission and 78% in complete molecular remission. Transplant\u2010related mortality (TRM) was 13%. Twenty\u2010four patients received DLI for residual disease. Acute GvHD, mostly Grades I\u2010II, occurred in 18% of patients post\u2010transplant and in 24% of patients receiving DLI. In conclusion, the risk\u2010adapted approach using only partial TCD and preemptive escalated dose of DLI precluded the need for immunosuppressive medications and reduced the risk of significant GvHD without compromising engraftment and long\u2010term disease control. Am. J. Hematol. 2012. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23263","type":"journal-article","created":{"date-parts":[[2012,5,14]],"date-time":"2012-05-14T10:34:49Z","timestamp":1336991689000},"page":"875-879","source":"Crossref","is-referenced-by-count":8,"title":["Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: Risk stratified approach with a long\u2010term follow\u2010up"],"prefix":"10.1002","volume":"87","author":[{"given":"Tsila","family":"Zuckerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuhad","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riva","family":"Fineman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldad J.","family":"Dann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishai","family":"Ofran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Gavish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Faibish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dvora","family":"Sahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eti","family":"Hertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond","family":"Sabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Reisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,27]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.38"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3547"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1928"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2575"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116475"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.211"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0711"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2139"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23427"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8154"},{"key":"e_1_2_7_14_2","doi-asserted-by":"crossref","first-page":"186a","DOI":"10.1182\/blood.V112.11.186.186","article-title":"International Randomized study of interferon versus STI571 (IRIS) 7\u2010year follow\u2010up: Sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia inchronic phase (CMLCP) treated with imatinib (IM)","volume":"112","author":"O'Brien SG","year":"2008","journal-title":"Blood"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.84"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03030-X"},{"key":"e_1_2_7_21_2","first-page":"513","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long\u2010term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"91","author":"Gratwohl A","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.561"},{"key":"e_1_2_7_23_2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1182\/blood.V94.2.434","article-title":"T\u2010cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic\u2010phase chronic myelogenous leukemia patients undergoing HLA\u2010identical sibling marrow transplantation","volume":"94","author":"Drobyski WR","year":"1999","journal-title":"Blood"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200004150-00025"},{"key":"e_1_2_7_25_2","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka D","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403135"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm525"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705377"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04955.x"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1615"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.1.67"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.2.397"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705180"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2008.07.002"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700677"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05138.x"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-162388"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.08.001"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-301341"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237115"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-302679"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-038943"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.05.002"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23263","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T21:20:24Z","timestamp":1696972824000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,27]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1002\/ajh.23263"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23263","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,27]]}}}